DOR BioPharma

Biotechnology Research • • 21-50 Employees

Company overview

Headquarters	XX
Website	dorbiopharma.com
NAICS	541714
Keywords	Pharmaceutical Drug Development
Employees	21-50

Key Contacts at DOR BioPharma

Dor Cohen

Director

Alison Bawden

Director

DOR BioPharma Email Formats

DOR BioPharma uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 45.6% of the time.

Format	Example	Percentage
{first name}.{last name}@company.com	john.doe@company.com	45.6%
{first name initial}{last name}@company.com	{first name initial}doe@company.com	22.3%
{first name}@company.com	john@company.com	15.1%
{first name}{last name}@company.com	johndoe@company.com	9.8%
{first name}_{last name}@company.com	john_doe@company.com	7.2%

About DOR BioPharma

DOR BioPharma, Inc. ( DOR ) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR’s lead product, orBec® (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of allogeneic hematopoietic cell transplantation.

DOR BioPharma revenue & valuation

Annual revenue	$2,652,205
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$8,500,000
Total funding	No funding